S&P 500   3,979.67 (+0.22%)
DOW   32,461.47 (+0.69%)
QQQ   308.74 (-0.69%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
S&P 500   3,979.67 (+0.22%)
DOW   32,461.47 (+0.69%)
QQQ   308.74 (-0.69%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
S&P 500   3,979.67 (+0.22%)
DOW   32,461.47 (+0.69%)
QQQ   308.74 (-0.69%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
S&P 500   3,979.67 (+0.22%)
DOW   32,461.47 (+0.69%)
QQQ   308.74 (-0.69%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
NASDAQ:OTIC

Otonomy - OTIC Stock Forecast, Price & News

$0.11
0.00 (0.00%)
(As of 03/27/2023 12:57 PM ET)
Add
Compare
Today's Range
$0.11
$0.11
50-Day Range
$0.10
$0.12
52-Week Range
$0.06
$2.54
Volume
97,908 shs
Average Volume
1.01 million shs
Market Capitalization
$7.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Otonomy MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
2,807.0% Upside
$3.25 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.08mentions of Otonomy in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars


OTIC stock logo

About Otonomy (NASDAQ:OTIC) Stock

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Stock News Headlines

The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Otonomy, Inc.: Otonomy Provides Corporate Update
Otonomy Provides Corporate Update
Why Is Otonomy (OTIC) Stock Up 97% Today?
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
See More Headlines
Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Company Calendar

Last Earnings
11/10/2021
Today
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTIC
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.25
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$0.50
Forecasted Upside/Downside
+2,827.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-51,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
67,780,000
Market Cap
$7.61 million
Optionable
Optionable
Beta
1.58

Key Executives

  • Paul E. Cayer
    President, CFO, Secretary & Chief Business Officer
  • Anna Stepannenko
    Vice President -Technical operations
  • Fabrice Piu
    Vice President-Research & Preclinical Development
  • David Skarinsky
    Vice President-Clinical
  • Jeffery J. Anderson
    Vice President-Clinical Sciences













OTIC Stock - Frequently Asked Questions

Should I buy or sell Otonomy stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OTIC, but not buy additional shares or sell existing shares.
View OTIC analyst ratings
or view top-rated stocks.

What is Otonomy's stock price forecast for 2023?

3 equities research analysts have issued 12-month target prices for Otonomy's shares. Their OTIC share price forecasts range from $0.50 to $6.00. On average, they anticipate the company's share price to reach $3.25 in the next year. This suggests a possible upside of 2,827.9% from the stock's current price.
View analysts price targets for OTIC
or view top-rated stocks among Wall Street analysts.

How have OTIC shares performed in 2023?

Otonomy's stock was trading at $0.0871 at the start of the year. Since then, OTIC stock has increased by 27.4% and is now trading at $0.1110.
View the best growth stocks for 2023 here
.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) released its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). During the same period in the previous year, the firm posted ($0.22) earnings per share.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Who are Otonomy's major shareholders?

Otonomy's stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Allen Weber, Jay Lichter, Robert Michael Savel II and Vickie L Capps.
View institutional ownership trends
.

How do I buy shares of Otonomy?

Shares of OTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $0.11.

How much money does Otonomy make?

Otonomy (NASDAQ:OTIC) has a market capitalization of $7.61 million and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190.

This page (NASDAQ:OTIC) was last updated on 3/27/2023 by MarketBeat.com Staff